Evidence map›Paper›PMID 30410781›Full record

ArticleMaternal health, neonatology and perinatology2018

Pregnancy gestation at delivery and breast milk production: a secondary analysis from the

Elizabeth V Asztalos, Alex Kiss, Orlando P da Silva, Marsha Campbell-Yeo, Shinya Ito, David Knoppert, EMPOWER Study Collaborative Group

Open access · goldAbstract read
In one paragraph

Article in Maternal health, neonatology and perinatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Elizabeth V Asztalos1Department of Newborn and Developmental Paediatrics, Sunnybrook Health Sciences Centre, University of Toronto, M4-230, 2075 Bayview Ave, Toronto, ON M4N 3M5 Canada.ORCID 0000-0002-9468-2860
Alex Kiss2Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON Canada.
Orlando P da Silva3Perinatal and Women's Health, London Health Sciences Centre, Western University, London, ON Canada.
Marsha Campbell-Yeo4School of Nursing, Departments of Pediatrics, Psychology and Neuroscience, Dalhousie University and Izaak Walton Killam Health Centre, Halifax, NS Canada.
Shinya Ito5Division of Clinical Pharmacology & Toxicology, Department of Paediatrics, Hospital for Sick Children, University of Toronto, Toronto, ON Canada.
David Knoppert6School of Pharmacy (D.K.), University of Waterloo, Kitchener, ON Canada.
EMPOWER Study Collaborative Group
Sunnybrook Health Science Centre · CAUniversity of Waterloo · CAWestern University · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPreterm birth alters the normal sequence of lactogenesis. Lactogenesis I may not yet have started when mothers of very preterm infants (≤ 29 weeks gestation) have given birth. Preterm infants are too small or too ill to initiate suckling in the immediate postpartum period thus altering the normal cascade of event for lactogenesis II. With an increasing demand for mother's own milk as a primary source of nutritional support in the care of very small and preterm infants, mothers of these infants are often at risk of expressing inadequate amounts of milk. The use of galactogogues is often considered when mothers of preterm infants are still having challenges in breast milk production. What is not clear in the literature is the role that pregnancy gestation at birth plays in successful response to galactogogues. Our objective for this study was to evaluate the role of pregnancy gestation at birth on a mother's response to the treatment interventions in the

methodsFor this analysis, the study participants are the 90 mothers who participated in the

resultsOn day 14 of the study treatment, there was no significant difference in the proportion of mothers in the 23-26 weeks gestation group (72.9%) compared to those in the 27-29 weeks gestation group (64.2%), OR 1.51 (95% CI 0.60, 3.78;

conclusionThis secondary analysis was able to demonstrate that mothers of very preterm infants, < 30 weeks gestation at birth, were able to respond to the study treatment in a similar fashion regardless of gestation at birth. If non-pharmacologic approaches are unsuccessful, then a 14-day treatment of domperidone may be considered to enhance breast milk production, even in the lowest gestational ages at delivery.

trial registration

Indexed as

Breast milk productionDomperidoneMothers of preterm infants

Identifiers

PMID30410781
PMCPMC6217780
OpenAlexW2891516272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.